2, when administered in combination with chemotherapy
Research gap analysis derived from 3 medicine papers in our local library.
The gap
2, when administered in combination with chemotherapy, may constitute a clinically feasible and potentially beneficial ther- apeutic strategy for patients with advanced gastric cancer requiring maintenance hemodialysis—an exceptionally chall
Evidence profile
Stated in the conclusions and discussion and cells future research sections of the source papers, classified as general, spanning 3 journals.
Research trend
Established — well-defined area with open sub-problems.
Supporting evidence — 3 representative gaps
- Solitary adrenal metastatic adenocarcinoma one year after radical gastrectomy for gastric cancer: a case report (2026) · Frontiers in Medicine · doi
Systemic chemotherapy combined with immunotherapy showed potential eÿcacy and tolerability in this specific case and warrants further investigation in larger cohorts, might oer a promising therapeutic option for patients with recurrent or metastatic gastric cancer; however, the optimal treatment strategy should be determined on an individualized basis.
generalstated in conclusionsevidence 5/5Keywords: systemic chemotherapy combined immunotherapy potential cacy tolerability specific case warrants further investigation larger cohorts promising - Zolbetuximab combined with chemotherapy in a patient with CLDN18.2-positive advanced gastric cancer undergoing hemodialysis: a case report (2026) · Frontiers in Oncology · doi
2, when administered in combination with chemotherapy, may constitute a clinically feasible and potentially beneficial ther- apeutic strategy for patients with advanced gastric cancer requiring maintenance hemodialysis—an exceptionally challenging clinical population that is traditionally excluded from standard systemic therapy and lacks evidence-based treatment guidance.
generalstated in discussionevidence 5/5Keywords: administered combination chemotherapy constitute clinically feasible potentially bene cial ther apeutic strategy patients advanced gastric - Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer (2026) · World Journal of Gastroenterology · doi
Further studies are needed to confirm the efficacy and safety of the PAC regimen in larger patient populations. - The optimal duration and dosage of immunotherapy and apatinib in the treatment of gastric cancer require further investigation. - The study highlights the need for continued research into the development of novel therapies for locally advanced gastric cancer.
generalstated in cells future researchevidence 5/5Keywords: further studies needed confirm efficacy safety pac regimen
Questions about this gap
Explore this gap further
Run this gap as a query across open scholarly engines for the latest related literature.
Working on this gap? Review it with us.
Science AI Journal reviews manuscripts in one pass with 8 specialised AI agents calibrated on 69,000+ real peer reviews.
Tools for your next paper
Related gaps in Medicine
- With larger sample sizes are needed to confirmFurther studies with larger sample sizes are needed to confirm these findings and explore their clinical implications.
- Designs across diverse populations to addressDesigns across diverse populations to address these limitations and confirm the long-term implications of our findings.
- There are certain concerns with According to this reviewThere are certain concerns with According to this review, biomarkers are playing an increasingly important role in cancer detection, prognos…
- That should be considered when interpreting the resultsthat should be considered when interpreting the results. First, the retrospective nature of the study may introduce biases related to data c…